Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent a growing global health problem linked to obesity, insulin resistance, and dyslipidemia. MASLD often leads to fibrosis, cirrhosis, and hepatoc...

Full description

Bibliographic Details

Published in:	Current Issues in Molecular Biology
Main Authors:	Elizabeta Knezović, Marija Hefer, Suzana Blažanović, Ana Petrović, Vice Tomičić, Nika Srb, Damir Kirner, Robert Smolić, Martina Smolić
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Subjects:	MASLD MASH resmetirom THR-β agonists
Online Access:	https://www.mdpi.com/1467-3045/47/3/154